HM
VRTX icon

HealthCor Management’s Vertex Pharmaceuticals VRTX Stock Holding History

HealthCor Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-130,290
Closed -$23.6M – 85
2021
Q3 		$23.6M Buy
130,290
+12,330
+10% +$2.41M 1.02% 28
2021
Q2 		$23.8M Sell
117,960
-548,500
-82% -$115M 0.95% 35
2021
Q1 		$143M Buy
666,460
+83,170
+14% +$18.3M 5.07% 2
2020
Q4 		$138M Buy
583,290
+220,900
+61% +$50.7M 5.32% 3
2020
Q3 		$98.6M Buy
362,390
+336,770
+1,314% +$92.9M 3.95% 12
2020
Q2 		$7.44M Buy
+25,620
New +$6.95M 0.31% 39
2020
Q1 		– Sell
-65,860
Closed -$14.4M – 61
2019
Q4 		$14.4M Sell
65,860
-613,830
-90% -$124M 0.51% 43
2019
Q3 		$115M Buy
679,690
+141,250
+26% +$25M 4.35% 6
2019
Q2 		$98.7M Buy
538,440
+199,670
+59% +$34.9M 3.83% 6
2019
Q1 		$62.3M Buy
338,770
+145,960
+76% +$27M 2.52% 15
2018
Q4 		$32M Sell
192,810
-9,370
-5% -$1.62M 1% 29
2018
Q3 		$39M Sell
202,180
-143,370
-41% -$25.5M 1.29% 28
2018
Q2 		$58.7M Buy
345,550
+195,760
+131% +$30.3M 1.86% 21
2018
Q1 		$24.4M Sell
149,790
-575,210
-79% -$94M 0.83% 38
2017
Q4 		$109M Buy
725,000
+690,050
+1,974% +$102M 3.54% 13
2017
Q3 		$5.31M Sell
34,950
-573,476
-94% -$86.3M 0.18% 39
2017
Q2 		$78.4M Sell
608,426
-416,574
-41% -$50.1M 2.83% 12
2017
Q1 		$112M Buy
+1,025,000
New +$90.2M 5.14% 8
2016
Q1 		– Sell
-471,970
Closed -$59.4M – 51
2015
Q4 		$59.4M Sell
471,970
-178,030
-27% -$21.5M 3.61% 12
2015
Q3 		$67.7M Buy
650,000
+200,000
+44% +$25.7M 3.81% 12
2015
Q2 		$55.6M Buy
450,000
+175,000
+64% +$22.1M 2.8% 13
2015
Q1 		$32.4M Buy
+275,000
New +$32.9M 1.55% 27
2014
Q3 		– Sell
-250,000
Closed -$23.8M – 61
2014
Q2 		$23.7M Buy
+250,000
New +$17.5M 1.19% 30
2013
Q3 		– Sell
-775,000
Closed -$62M – 68
2013
Q2 		$62M Buy
+775,000
New +$57.1M 3.75% 8

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

HealthCor Management's VRTX Position: Q4 2021 in Review

HealthCor Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 130,290 shares — an estimated $23.6M sold.

HealthCor Management first reported a position in VRTX in Q2 2013 and held it in 24 quarters. The position peaked at $143M in Q1 2021. 1,034 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

  • HealthCor Management reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • HealthCor Management sold 130,290 Vertex Pharmaceuticals shares in Q4 2021, an estimated $23.6M.
  • HealthCor Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 24 quarters.
  • HealthCor Management's Vertex Pharmaceuticals position peaked at $143M in Q1 2021.
  • 1,034 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on HealthCor Management's 13F filing for Q4 2021, filed 14 Feb 2022.